{"id":47756,"date":"2025-11-13T23:35:38","date_gmt":"2025-11-13T15:35:38","guid":{"rendered":"https:\/\/flcube.com\/?p=47756"},"modified":"2025-11-13T23:35:39","modified_gmt":"2025-11-13T15:35:39","slug":"legend-biotech-reports-524-m-carvykti-sales-fda-updates-q3-loss","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=47756","title":{"rendered":"Legend Biotech Reports $524\u202fM CARVYKTI Sales, FDA Updates &amp; Q3 Loss"},"content":{"rendered":"\n<p>Legend Biotech\u202f(<a href=\"https:\/\/www.google.com\/finance\/quote\/LEGN:NASDAQ\">NASDAQ: LEGN<\/a>) published the unaudited financial results for fiscal\u202fQuarter\u202f3\u202f2025 (2025Q3) on 12\u202fNov\u202f2025. The flagship CAR\u2011T therapy <strong>CARVYKTI (ciltacabtagene autoleucel \u2013 cilta\u2011cel)<\/strong> generated net trade sales of <strong>\u2248\u202fUSD\u202f524\u202fmillion<\/strong> and continues to enroll patients at the newly\u2011activated Tech\u202fLane facility in Belgium. A <strong>US\u202fFDA<\/strong>\u2011 and <strong>European Commission (EC)<\/strong>\u2011approved label update adds overall\u2011survival data from the Phase\u202f3 CARTITUDE\u20114 study, while also incorporating a risk of immune\u2011effector\u2011cell\u2011associated enterocolitis.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-q3-2025-highlights\">Q3 2025 Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue<\/strong> \u2013 Net trade sales of <strong>USD\u202f524\u202fmillion<\/strong> and <strong>USD\u202f10.5\u202fmillion<\/strong> in license revenue (Novartis\u2011LB2102 &amp; DLL\u20113 CAR\u2011T agreements).<\/li>\n\n\n\n<li><strong>Treatment Reach<\/strong> \u2013 >\u202f9,000 patients treated to date.<\/li>\n\n\n\n<li><strong>Production<\/strong> \u2013 Commercial manufacturing now underway at the Tech\u202fLane plant in Belgium.<\/li>\n\n\n\n<li><strong>Financial Position<\/strong> \u2013 Cash &amp; equivalents: <strong>\u2248\u202fUSD\u202f1.0\u202fbillion<\/strong> (as of 30\u202fSep\u202f2025).<\/li>\n\n\n\n<li><strong>Operating Result<\/strong> \u2013 Net loss of <strong>USD\u202f39.7\u202fmillion<\/strong> in 2025Q3.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-label-updates-amp-new-data\">Label Updates &amp; New Data<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CARTITUDE\u20114<\/strong> \u2013 The pivotal study delivered a <strong>statistically significant overall survival (OS) advantage<\/strong> for CARVYKTI over standard pomalidomide\u2011bortezomib\u2011dexamethasone (PVd) and daratumumab\u2011pomalidomide\u2011dexamethasone (DPd) in relapsed\/lenalidomide\u2011refractory multiple myeloma.<\/li>\n\n\n\n<li><strong>Regulatory Endorsements<\/strong> \u2013 Both the <strong>FDA<\/strong> and the <strong>European Commission (EC)<\/strong> approved the OS\u2011based label extension.<\/li>\n\n\n\n<li><strong>Safety Note<\/strong> \u2013 The label now cites the <strong>risk of immune\u2011effector\u2011cell\u2011associated enterocolitis<\/strong> based on clinical trial outcomes and post\u2011marketing observations.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnerships-amp-licensing\">Partnerships &amp; Licensing<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Source<\/th><th>2025Q3 Revenue<\/th><th>Notes<\/th><\/tr><\/thead><tbody><tr><td>Novartis <strong>LB2102 DLL\u20113<\/strong> license<\/td><td><strong>USD\u202f10.5\u202fM<\/strong><\/td><td>One\u2011time royalty from a separate CAR\u2011T platform.<\/td><\/tr><tr><td>Janssen collaboration on CARVYKTI sales<\/td><td>\u2013<\/td><td>Collaboration revenue recognised as part of CAR\u2011T product sales.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>These streams demonstrate the firm\u2019s expanding commercialization footprint beyond the primary CARVYKTI product line.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investor-focused-takeaway\">Investor\u2011Focused Takeaway<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Scale<\/strong> \u2013 Treating >\u202f9,000 patients underlines CARVYKTI\u2019s market penetration and revenue momentum.<\/li>\n\n\n\n<li><strong>Cash Position<\/strong> \u2013 Near\u2011USD\u202f1\u202fbillion cash reserves provide runway for continued R&amp;D and production ramp\u2011up.<\/li>\n\n\n\n<li><strong>Profitability Gap<\/strong> \u2013 A <strong>$39.7\u202fmillion<\/strong> net loss signals ongoing investment in product development, licensing, and clinical\u2011streamline operations despite strong sales.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011looking Statements<\/h3>\n\n\n\n<p>The information herein is forward\u2011looking and subject to risks that may cause actual results to differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Legend Biotech\u202f(NASDAQ: LEGN) published the unaudited financial results for fiscal\u202fQuarter\u202f3\u202f2025 (2025Q3) on 12\u202fNov\u202f2025. The flagship&#8230;<\/p>\n","protected":false},"author":1,"featured_media":47762,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[30,21,27,112,873],"class_list":["post-47756","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biotech","tag-car-t","tag-finanical-reports","tag-legend-biotech","tag-nasdaq-legn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Legend Biotech Reports $524\u202fM CARVYKTI Sales, FDA Updates &amp; Q3 Loss - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Legend Biotech\u202f(NASDAQ: LEGN) published the unaudited financial results for fiscal\u202fQuarter\u202f3\u202f2025 (2025Q3) on 12\u202fNov\u202f2025. The flagship CAR\u2011T therapy CARVYKTI (ciltacabtagene autoleucel \u2013 cilta\u2011cel) generated net trade sales of \u2248\u202fUSD\u202f524\u202fmillion and continues to enroll patients at the newly\u2011activated Tech\u202fLane facility in Belgium. A US\u202fFDA\u2011 and European Commission (EC)\u2011approved label update adds overall\u2011survival data from the Phase\u202f3 CARTITUDE\u20114 study, while also incorporating a risk of immune\u2011effector\u2011cell\u2011associated enterocolitis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=47756\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Legend Biotech Reports $524\u202fM CARVYKTI Sales, FDA Updates &amp; Q3 Loss\" \/>\n<meta property=\"og:description\" content=\"Legend Biotech\u202f(NASDAQ: LEGN) published the unaudited financial results for fiscal\u202fQuarter\u202f3\u202f2025 (2025Q3) on 12\u202fNov\u202f2025. The flagship CAR\u2011T therapy CARVYKTI (ciltacabtagene autoleucel \u2013 cilta\u2011cel) generated net trade sales of \u2248\u202fUSD\u202f524\u202fmillion and continues to enroll patients at the newly\u2011activated Tech\u202fLane facility in Belgium. A US\u202fFDA\u2011 and European Commission (EC)\u2011approved label update adds overall\u2011survival data from the Phase\u202f3 CARTITUDE\u20114 study, while also incorporating a risk of immune\u2011effector\u2011cell\u2011associated enterocolitis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=47756\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-13T15:35:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-13T15:35:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1311.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47756#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47756\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Legend Biotech Reports $524\u202fM CARVYKTI Sales, FDA Updates &amp; Q3 Loss\",\"datePublished\":\"2025-11-13T15:35:38+00:00\",\"dateModified\":\"2025-11-13T15:35:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47756\"},\"wordCount\":350,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47756#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1311.webp\",\"keywords\":[\"Biotech\",\"CAR-T\",\"Finanical Reports\",\"Legend Biotech\",\"NASDAQ: LEGN\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47756#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47756\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=47756\",\"name\":\"Legend Biotech Reports $524\u202fM CARVYKTI Sales, FDA Updates &amp; Q3 Loss - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47756#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47756#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1311.webp\",\"datePublished\":\"2025-11-13T15:35:38+00:00\",\"dateModified\":\"2025-11-13T15:35:39+00:00\",\"description\":\"Legend Biotech\u202f(NASDAQ: LEGN) published the unaudited financial results for fiscal\u202fQuarter\u202f3\u202f2025 (2025Q3) on 12\u202fNov\u202f2025. The flagship CAR\u2011T therapy CARVYKTI (ciltacabtagene autoleucel \u2013 cilta\u2011cel) generated net trade sales of \u2248\u202fUSD\u202f524\u202fmillion and continues to enroll patients at the newly\u2011activated Tech\u202fLane facility in Belgium. A US\u202fFDA\u2011 and European Commission (EC)\u2011approved label update adds overall\u2011survival data from the Phase\u202f3 CARTITUDE\u20114 study, while also incorporating a risk of immune\u2011effector\u2011cell\u2011associated enterocolitis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47756#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47756\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47756#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1311.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1311.webp\",\"width\":1080,\"height\":608,\"caption\":\"Legend Biotech Reports $524\u202fM CARVYKTI Sales, FDA Updates & Q3 Loss\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47756#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Legend Biotech Reports $524\u202fM CARVYKTI Sales, FDA Updates &amp; Q3 Loss\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Legend Biotech Reports $524\u202fM CARVYKTI Sales, FDA Updates &amp; Q3 Loss - Insight, China&#039;s Pharmaceutical Industry","description":"Legend Biotech\u202f(NASDAQ: LEGN) published the unaudited financial results for fiscal\u202fQuarter\u202f3\u202f2025 (2025Q3) on 12\u202fNov\u202f2025. The flagship CAR\u2011T therapy CARVYKTI (ciltacabtagene autoleucel \u2013 cilta\u2011cel) generated net trade sales of \u2248\u202fUSD\u202f524\u202fmillion and continues to enroll patients at the newly\u2011activated Tech\u202fLane facility in Belgium. A US\u202fFDA\u2011 and European Commission (EC)\u2011approved label update adds overall\u2011survival data from the Phase\u202f3 CARTITUDE\u20114 study, while also incorporating a risk of immune\u2011effector\u2011cell\u2011associated enterocolitis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=47756","og_locale":"en_US","og_type":"article","og_title":"Legend Biotech Reports $524\u202fM CARVYKTI Sales, FDA Updates &amp; Q3 Loss","og_description":"Legend Biotech\u202f(NASDAQ: LEGN) published the unaudited financial results for fiscal\u202fQuarter\u202f3\u202f2025 (2025Q3) on 12\u202fNov\u202f2025. The flagship CAR\u2011T therapy CARVYKTI (ciltacabtagene autoleucel \u2013 cilta\u2011cel) generated net trade sales of \u2248\u202fUSD\u202f524\u202fmillion and continues to enroll patients at the newly\u2011activated Tech\u202fLane facility in Belgium. A US\u202fFDA\u2011 and European Commission (EC)\u2011approved label update adds overall\u2011survival data from the Phase\u202f3 CARTITUDE\u20114 study, while also incorporating a risk of immune\u2011effector\u2011cell\u2011associated enterocolitis.","og_url":"https:\/\/flcube.com\/?p=47756","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-13T15:35:38+00:00","article_modified_time":"2025-11-13T15:35:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1311.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=47756#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=47756"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Legend Biotech Reports $524\u202fM CARVYKTI Sales, FDA Updates &amp; Q3 Loss","datePublished":"2025-11-13T15:35:38+00:00","dateModified":"2025-11-13T15:35:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=47756"},"wordCount":350,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=47756#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1311.webp","keywords":["Biotech","CAR-T","Finanical Reports","Legend Biotech","NASDAQ: LEGN"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=47756#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=47756","url":"https:\/\/flcube.com\/?p=47756","name":"Legend Biotech Reports $524\u202fM CARVYKTI Sales, FDA Updates &amp; Q3 Loss - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=47756#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=47756#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1311.webp","datePublished":"2025-11-13T15:35:38+00:00","dateModified":"2025-11-13T15:35:39+00:00","description":"Legend Biotech\u202f(NASDAQ: LEGN) published the unaudited financial results for fiscal\u202fQuarter\u202f3\u202f2025 (2025Q3) on 12\u202fNov\u202f2025. The flagship CAR\u2011T therapy CARVYKTI (ciltacabtagene autoleucel \u2013 cilta\u2011cel) generated net trade sales of \u2248\u202fUSD\u202f524\u202fmillion and continues to enroll patients at the newly\u2011activated Tech\u202fLane facility in Belgium. A US\u202fFDA\u2011 and European Commission (EC)\u2011approved label update adds overall\u2011survival data from the Phase\u202f3 CARTITUDE\u20114 study, while also incorporating a risk of immune\u2011effector\u2011cell\u2011associated enterocolitis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=47756#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=47756"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=47756#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1311.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1311.webp","width":1080,"height":608,"caption":"Legend Biotech Reports $524\u202fM CARVYKTI Sales, FDA Updates & Q3 Loss"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=47756#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Legend Biotech Reports $524\u202fM CARVYKTI Sales, FDA Updates &amp; Q3 Loss"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1311.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47756"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47756\/revisions"}],"predecessor-version":[{"id":47764,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47756\/revisions\/47764"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/47762"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=47756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=47756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}